| 要約: | Faecal microbiota transplantation (FMT) is regarded as an efficacious treatment for recurrent <i>C. difficile</i> infection. Unfortunately, widespread patient access is hindered by regulatory hurdles, which are the primary barriers to incorporating FMT into clinical practice. At the European and International level, there is no uniform perspective on FMT classification, and a coordinated effort is desirable to solve this regulatory puzzle. In this communication, we report the regulatory principles and the implementation approach for FMT application in Italy. Our experience suggests that the EU Tissue and Cell Directives are suited to ensure safe and efficient FMT for <i>C. difficile</i> management, especially through extensive high-quality donor selection and full traceability maintenance.
|
|---|
